Completed PHASE2 INTERVENTIONAL NCT00098033

Investigation of Clofarabine in Acute Leukemias

Phase II Clinical and Pharmacodynamic Investigation of Clofarabine in Acute Leukemias

Sponsor: University of Texas

Conditions Acute Lymphocytic Leukemia Acute Myelogenous Leukemia Chronic Myelogenous Leukemia

Interventions clofarabine

Updated 5 times since 2017 Last updated: Mar 24, 2015 Started: Sep 30, 2002 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00098033, this PHASE2 trial focuses on Acute Lymphocytic Leukemia and Acute Myelogenous Leukemia and remains completed. Sponsored by University of Texas, it has been updated 5 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Texas

Data source: FDA Office of Orphan Products Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.